Education
About Us
Working with TipRanks
Follow Us
Elutia (ELUT)
NASDAQ:ELUT
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.21Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced clear operational and strategic progress — including an $88M asset sale, stronger margins, $44.4M (cash + escrow), regulatory submissions for NXT 41, manufacturing capacity, strong KOL engagement, and organizational hires — against ongoing near-term financial losses, modest current revenue scale, and regulatory/timing risk for the pivotal NXT 41X approval (targeted for late H1 2027). The company appears well-resourced and focused on a high-impact product opportunity, but execution risk and timeline uncertainty remain.Company Guidance
Quarterly Revenue Growth
Revenue of $3.3M in Q4 FY2025 versus $2.8M year-ago quarter, up 16% year-over-year, driven by return to direct distribution for cardiovascular and SimpliDerm product lines.
Improved Adjusted Gross Margin
Adjusted gross margin for Q4 was 66.8%, up 12 percentage points from 56.5% in the prior-year quarter, reflecting benefits of direct distribution and mix improvement.
Strengthened Balance Sheet and Debt Payoff
Net cash position of $44.4M (cash on hand plus $8M in escrow) after paying off ~$28M of SWK debt; proceeds enabled by strategic asset sale.
Strategic Asset Sale
Sale of the bioenvelope business to Boston Scientific for $88M in 2025, providing validation of the platform and substantial liquidity to fund pipeline development.
Regulatory Progress — 41 Submission
NXT 41 (base matrix) submitted to FDA; company expects clearance in 2026 for 41 and anticipates NXT 41X clearance toward the end of H1 2027 with a planned second-half 2027 commercial launch for the drug-eluting 41X.
Validated Technology and Prior Product Traction
EluPro demonstrated commercial traction previously, achieving an $18M run rate and rapid uptake (194 VACs in nine months), supporting platform credibility for 41/41X development.
Manufacturing Capacity
Company reports manufacturing capability sufficient for an estimated ~$120M in revenue-generating capacity for 41X on a single shift, supporting initial commercial scale.
Commercial and Organizational Strengthening
Key hires and board additions including new Chief Commercial Officer Pete Ligotti (30-year commercial background) and new board member Guido Nils; active KOL engagement and VAC experience expected to support launch readiness.
SimpliDerm Strategic Optionality and Payer Coverage
Exploring strategic options for SimpliDerm — asset described as plug-and-play, patent protected, EBITDA accretive, with ~100 million lives covered across Anthem, UnitedHealthcare, and regional plans.
Workforce and Culture Recognition
Great Place to Work certification; workforce metrics: 54% women, 62% of leadership roles held by women, 50% with advanced degrees, one-third of organization holding doctorates, average tenure 6.3 years — positive recruiting and retention implications.
Regulatory and Commercial Focus
Clear strategic focus on NXT 41/41X with explicit regulatory pathway and resource allocation (development, manufacturing, commercial) to accelerate approval and launch.
Return to Nasdaq Compliance and Capital Structure Simplification
Conversion of Class B shares and sale into the market reduced an overhang; as of year-end 42.8M common shares outstanding plus 4.5M pre-funded warrants (total 47.3M), and company returned to compliance with Nasdaq listing requirements.
ELUT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ELUT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 11, 2026 | $1.09 | $1.15 | +5.50% |
Nov 06, 2025 | $0.94 | $0.90 | -4.99% |
Aug 14, 2025 | $2.15 | $2.02 | -6.05% |
May 08, 2025 | $1.99 | $2.08 | +4.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Elutia (ELUT) report earnings?
Elutia (ELUT) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is Elutia (ELUT) earnings time?
Elutia (ELUT) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELUT EPS forecast?
ELUT EPS forecast for the fiscal quarter 2026 (Q1) is -0.15.